Exhibit 99.1

Theragenics® Reports Record Revenue with 2009 Results

$78.3 Million is Highest Annual Revenue in 29-Year History

Pro forma Organic Growth of 10% in Surgical Products Segment for 2009

Supply and Reseller Agreement with Core Oncology adds to Momentum for 2010

BUFORD, Ga.--(BUSINESS WIRE)--February 11, 2010--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008. The terms "Company", "we", "us", or "our" mean Theragenics Corporation and all entities included in our consolidated financial statements.


  • Recorded consolidated revenue of $18.7 million in the fourth quarter and $78.3 million for the full year.
  • Achieved 17% organic revenue growth in our surgical products business for the fourth quarter and 10% pro forma organic growth for the year, compared to 2008.
  • EPS for the quarter was $0.01, compared to a loss of $1.89 per share in 2008. Excluding 2008 impairment charges, EPS was $0.01 in the fourth quarter of 2008.
  • EPS for the year was $0.09, compared to a loss of $1.77 per share in 2008. Excluding 2008 impairment charges, EPS was $0.13 for 2008.
  • Completed the year with cash and cash equivalent of $45.3 million and outstanding borrowings under our credit agreement of $30.3 million for a net positive cash position of $15.0 million.
  • Adjusted EBITDA was $13.1 million and cash flow from operations was $11.6 million for 2009.
  • In early 2010, we announced a supply and reseller agreement with Core Oncology for our brachytherapy segment. Core is a recognized leader in the brachytherapy industry. We expect Core to represent at least 10% of our brachytherapy segment revenue in 2010.
  • Research and Development (“R&D”) expenses increased $860,000 over 2008. This reflects investments to support future growth in the surgical products segment, a strategic initiative that was launched in late 2008.
  • Continued our initiative to update and standardize our information technology (“IT”) systems and infrastructure across all of our businesses.
  • Purchased a larger facility for increased capacity in our specialty needle manufacturing. We expect to complete improvements and move to this new facility in 2010.
  • Capital expenditures were $5.0 million in 2009, reflecting our investments in manufacturing capacity for our surgical products business and in corporate wide IT.

The following information was filed by Theragenics Corp (TGX) on Thursday, February 11, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Theragenics Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Theragenics Corp.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account